Michelle Carr, Author at BioTuesdays

Executive Moves

Applied names John H. Johnson as EC; Shoshana Shendelman steps down as CEO

Applied Therapeutics (NASDAQ:APLT) has announced leadership changes, naming John H. Johnson as executive chairman (EC) and Les Funtleyder, formally CFO, as interim CEO. Shoshana Shendelman, MD, has stepped down from her...

December 20, 2024

Developments

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Mesoblast (ASX:MSB; NASDAQ:MESO) is rallying today after the company announced yesterday after market close that the FDA approved RYONCIL (remestemcel-L), an allogeneic (donor) bone marrow-derived mesenchymal stromal...

December 19, 2024

Markets

Clear Street initiates coverage of several healthcare stocks

Analysts Kaveri Pohlman, PhD and Bill Maughan, PhD from Clear Street, a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, have launched coverage of several healthcare names. “The...

December 11, 2024

Developments

PharmaJet spotlights Nature publication on Stratis IM System benefits

Closely held PharmaJet has announced that the peer-reviewed journal Nature has published findings from a U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 trial, demonstrating that the...

December 10, 2024

Developments

Profound Medical gains media attention for its incision- and radiation-free TULSA treatment for prostate cancer and/or BPH

Profound Medical’s (NASDAQ:PROF; TSX:PRN) CEO, Arun Menawat, recently sat down with Fierce Biotech to discuss how TULSA-PRO is revolutionizing prostate disease treatment. In the interview, Dr. Menawat noted...

December 9, 2024

Developments

FDA grants RMAT for combination of Affimed’s acimtamig and Artiva’s AlloNK

Affimed (NASDAQ:AFMD) announced that the FDA has granted regenerative medicine advanced therapy (RMAT) designation to its combination therapy involving Affimed’s innate cell engager (ICE) acimtamig, and Artiva...

December 5, 2024

Developments

Nkarta receives IND clearance for IST in MG; launches enrollment of Ntrust-2 trial

Nkarta (NASDQ:NKTX) announced the clearance of an investigational new drug clearance (IND) application for its investigator-sponsored trial (IST) evaluating NKX019 in patients with myasthenia gravis (MG), alongside the...

December 5, 2024

Developments

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a definitive co-sales and co-marketing agreement with Siemens Healthineers (XETRA:SHL) pursuant to which the companies will commercialize a new MRI-guided prostate...

December 2, 2024

Developments

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it will unveil its third TULSA-AI software module, UA Alignment Assistant at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society...

November 26, 2024

Markets

Leede Financial starts Nanalysis Scientific at buy; PT C$0.90

Leede Financial launched coverage of Nanalysis Scientific (TSXV: NSCI) (OTCQX: NSCIF) with a “speculative buy” rating and C$0.90 target price. The stock closed at $0.365 on November 22. Nanalysis operates two distinct...

November 25, 2024

Author - Michelle Carr

Applied names John H. Johnson as EC; Shoshana Shendelman steps down as CEO

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Clear Street initiates coverage of several healthcare stocks

PharmaJet spotlights Nature publication on Stratis IM System benefits

Profound Medical gains media attention for its incision- and radiation-free TULSA treatment for prostate cancer and/or BPH

FDA grants RMAT for combination of Affimed’s acimtamig and Artiva’s AlloNK

Nkarta receives IND clearance for IST in MG; launches enrollment of Ntrust-2 trial

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

Leede Financial starts Nanalysis Scientific at buy; PT C$0.90

Subscribe